



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Theodore Laetsch, M.D.

Committee: Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee (PedsODAC)

Meeting Date: June 20, 2019

I acknowledge that contingent upon public disclosure of the following financial interest related to the agenda item: during the afternoon session information will be presented to gauge investigator interest in exploring potential pediatric development plans for ONC201, sponsored by Oncoceutics, Inc., which is in early stages of development for adult and pediatric cancer indications. In addition to the adult indications, ONC201 is currently in early phase pediatric studies for diffuse intrinsic pontine glioma (DIPG). The subcommittee will consider and discuss issues concerning potential diseases to be studied, including but not limited to DIPG, patient populations to be included, and possible study designs in the development of this product for pediatric use. The discussion will also provide information to the Agency pertinent to the formulation of written requests for pediatric studies, if appropriate, I may be considered for participation in the advisory committee meeting described above.

<u>Type of Interest</u>	<u>Nature</u>	<u>Magnitude</u>
I. Personal/Immediate Family		
None		
II. Other Imputed Interests		
contract/grant	Pfizer (through the Children's Oncology Group), competing firm	Between \$0 – \$50,000 per year

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

/s/
Signature

5/30/19
Date